We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Array Technologies Inc | NASDAQ:ARRY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 3.06% | 13.46 | 10.00 | 19.00 | 13.98 | 13.35 | 13.57 | 4,630,191 | 05:00:05 |
From May 2019 to May 2024
BOULDER, Colo., Sept. 25, 2015 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will hold a conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial on Monday, September 28, 2015. Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, will lead the call.
The trials include a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2), a Phase 1b/2 combination trial of binimetinib and a CDK4/6 inhibitor in NRAS-mutant melanoma patients and a Phase 2 combination trial of encorafenib and an EGFR inhibitor with or without the addition of a PI3K inhibitor in patients with BRAF-mutant colorectal cancer. Data from these trials will be presented at the European Society of Medical Oncology's (ESMO) annual European Cancer Conference (ECC) or were presented at the 2015 ESMO World Congress of Gastrointestinal Cancer.
|
Conference Call Information | |
|
Date: |
Monday, September 28, 2015 |
|
Time: |
9:00 a.m. eastern time |
|
Toll-Free: |
(844) 464-3927 |
|
Toll: |
(765) 507-2598 |
|
Pass Code: |
43837177 |
|
Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/ky8z35w4/lan/en | |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
|
CONTACT: |
Tricia Haugeto |
|
Array BioPharma Inc. | |
|
(303) 386-1193 | |
|
thaugeto@arraybiopharma.com |
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-hold-conference-call-to-discuss-clinical-data-presentations-in-melanoma-and-colorectal-cancer-on-september-28-2015-300149033.html
SOURCE Array BioPharma
Copyright 2015 PR Newswire
1 Year Array Technologies Chart |
1 Month Array Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
